MDMA-Assisted Therapy for PTSD Faces Potential FDA Approval Next Year, Advocate Says

MDMA-assisted therapy for post-traumatic stress disorder (PTSD) could receive Food and Drug Administration (FDA) approval as early as January, according to a prominent advocate in the field, though significant challenges persist.

Rick Doblin, founder and former board member of the Multidisciplinary Association for Psychedelic Studies (MAPS), expressed strong optimism regarding the resubmitted application by Resilient Pharmaceuticals, formerly Lykos Therapeutics. "I would say that I'm very optimistic," Doblin told The Post, predicting a "very good chance" of approval by the end of the first quarter of 2027.

PTSD, which can develop after experiencing or witnessing a traumatic event, affects millions of Americans annually. Symptoms can include flashbacks, nightmares, severe anxiety, and intrusive thoughts. For individuals who have not found relief through traditional treatments, MDMA-assisted therapy has been explored as a potential new option.

In 2021, a clinical trial conducted by MAPS indicated that participants with PTSD who received MDMA alongside psychotherapy were twice as likely to recover compared to those who received psychotherapy with a placebo. This promising outcome fueled hopes for broader medical acceptance.

However, the path to approval has faced setbacks. In August 2024, the FDA rejected Lykos Therapeutics' initial application. The agency cited concerns about the reliability of clinical trial data, potential safety risks, and insufficient demonstration of the therapy's effectiveness. The FDA recommended an additional Phase 3 trial to address these apprehensions.

Resilient Pharmaceuticals reportedly resubmitted its application in August, this time without the additional Phase 3 trial previously requested. Instead, the company referenced research from other groups, including a Veterans Affairs study with long-term follow-up. MAPS confirmed the resubmission, though Resilient has not publicly commented.

Several factors contribute to the renewed optimism. Health and Human Services Secretary Robert F. Kennedy Jr. has supported the expedited research and approval of psychedelic therapies. In April, President Trump signed an executive order aimed at accelerating psychedelic research, and the FDA has issued priority review vouchers for psychedelic-based mental health treatments. Additionally, the Department of Defense is conducting studies on MDMA-assisted therapy for active-duty soldiers with PTSD, signaling growing institutional interest.

The increasing involvement of major pharmaceutical companies, such as Eli Lilly's acquisition of AtaiBeckley for $2.8 billion, also suggests a shifting landscape and greater investment in the field.

Despite the potential for regulatory approval, a significant obstacle remains: a shortage of qualified therapists trained to administer MDMA-assisted therapy. Doblin described this as an "acute" problem, noting that the estimated 13 million Americans with PTSD far outnumber the available trained professionals. Dr. Dave Rabin, a neuroscientist and MDMA psychotherapist, echoed these concerns, emphasizing the need to develop infrastructure for continuing medical education and address insurance reimbursement issues.

MAPS is planning to hold its first U.S. training session in December to help address the therapist shortage. Doblin stressed the importance of expanding training programs cautiously to ensure that therapy is administered by qualified practitioners.

The FDA declined to comment on the status of Resilient Pharmaceuticals' application, stating that information on unapproved applications is generally not releasable.